Orphazyme

MedTech

Oracle | September 16, 2021

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology. Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential n...

Medical

businesswire | October 19, 2023

Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa. The milestone marks a significant achievement in the company’s 35-year-history—its entrance into the therapeutics spa...

BioSpace | March 27, 2020

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Cell and Gene Therapy

Tachyon Therapeutics Inc. | August 25, 2022

Tachyon Therapeutics, Inc. a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application to develop TACH101 for the treatment of advanced solid tumors. "The approval of this IND marks a significant milestone for the Company, as TACH101 will be the first KDM4 inhibitor to enter clinical stage. ...